Search

Search Results

1. Doxorubicin

   in Dictionary of Toxicology

   Reference work entry 2024
   

2. Preparation of Doxorubicin Liposomes by Remote Loading Method

   Doxorubicin liposome is one of the most important nano-drug formulations. DOXIL, the first FDA-approved doxorubicin liposomes, is also the first...

   Jian Chen in Liposomes

   Protocol 2023
   

3. PBPK model of pegylated liposomal doxorubicin to simultaneously predict the concentration–time profile of encapsulated and free doxorubicin in tissues

   The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model to predict the concentrations of encapsulated and...

   Xuewei Cao, Kejun Li, ... Le Sun in Drug Delivery and Translational Research

   Article 05 August 2024
   

4. Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers

   Cardiotoxicity remains one of the major threats to cancer patients treated with the potent anticancer drug doxorubicin. It has become a significant...

   Li-Rong Yu, Varsha G. Desai in Biomarkers in Toxicology

   Reference work entry 2023
   

5. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors

   Objective

   The objective of this study was to investigate the impact of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac...

   Shanshan Ding, Shasha Xiong, ... Xiaoke Shang in Clinical and Translational Oncology

   Article 08 February 2024
   

6. Balancing efficacy and safety of doxorubicin-loaded albumin nanoparticles utilizing pH-sensitive doxorubicin-fatty acid prodrugs

   Albumin nanoparticles (ANPs) offer unique advantages for antitumor drug delivery system, including non-immunogenicity and inherent tumor-targeting...

   Yuanhao Yu, Shiyi Zuo, ... Jin Sun in Nano Research

   Article 29 February 2024
   

7. Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin

   Intrahepatic accumulation dominates organ distribution for most nanomedicines. However, obscure intrahepatic fate largely hampers regulation on their...

   Kuan Jiang, Kaisong Tian, ... Changyou Zhan in Nature Communications

   Article Open access 20 July 2024
   

8. Synthetic Antioxidant TS-13 Reduces the Cardiotoxicity of Doxorubicin

   Abstract

   The antitumor antibiotic doxorubicin, a member of a large group of anthracyclines, is widely and quite effectively used to treat patients...

   E. B. Menshchikova, R. A. Knyazev, ... N. V. Kandalintseva in Cell and Tissue Biology

   Article 12 August 2024
   

9. Nrf2: a dark horse in doxorubicin-induced cardiotoxicity

   Being a broad-spectrum anticancer drug, doxorubicin is indispensable for clinical treatment. Unexpectedly, its cardiotoxic side effects have proven...

   Xiaopeng Zhao, Zheng Tian, ... Dan Dong in Cell Death Discovery

   Article Open access 26 July 2023
   

10. Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway

    Breast cancer (BC) is a lethal disorder that threatens the life safety of the majority of females globally, with rising morbidity and mortality year...

    Guojian Shi, Xiaohua Li, ... Li Wang in Cell Biochemistry and Biophysics

    Article 27 February 2024
    

11. RIP3 regulates doxorubicin-induced intestinal mucositis via FUT2-mediated α-1,2-fucosylation

    Objective

    Intestinal mucositis is one of the common side effects of anti-cancer chemotherapy. However, the molecular mechanisms involved in mucositis...

    Wei Wen, Xiaomin Hu, ... Xiuqin Zhang in Inflammation Research

    Article 24 August 2024
    

12. Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis

    The pathogenesis of doxorubicin-induced cardiomyopathy remains unclear. This study was carried out to test our hypothesis that ADAM17 aggravates...

    Lin Xie, Fei Xue, ... Yun Zhang in Signal Transduction and Targeted Therapy

    Article Open access 16 October 2024
    

13. Structural Reorganization of Cell Membrane Models Caused by the Anticancer Antibiotic Doxorubicin

    Abstract

    The molecular mechanisms of the interaction of anticancer antibiotic doxorubicin with lipid cell membrane models have been investigated using...

    N. N. Novikova, M. V. Kovalchuk, ... S. N. Yakunin in Crystallography Reports

    Article 01 December 2023
    

14. STK32C modulates doxorubicin resistance in triple-negative breast cancer cells via glycolysis regulation

    Understanding the mechanisms underlying doxorubicin resistance in triple-negative breast cancer (TNBC) holds paramount clinical significance. In our...

    Huawei Xiao, Lei Liu, Shaoyan Huang in Molecular and Cellular Biochemistry

    Article 20 March 2024
    

15. Rifampicin efficacy against doxorubicin-induced cardiotoxicity in mice

    Background

    The toxic effect of doxorubicin on the heart limits its clinical usage in cancer therapy. This work intended to investigate, for the first...

    Omnia A. Basal, Rasha F. Zahran, Entsar A. Saad in The Egyptian Heart Journal

    Article Open access 21 August 2023
    

16. Cardioprotective Effects of Leucine Supplementation against Doxorubicin-Induced Cardiotoxicity

    Doxorubicin is one of the most important antitumor drugs used in oncology; however, its cardiotoxic effect limits the therapeutic use and raises...

    Lucas C. Guimarães, Thiago M. Fidale, ... Elmiro S. Resende in Cardiovascular Toxicology

    Article 02 January 2024
    

17. A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging

    The population of cancer survivors is rapidly increasing due to improving healthcare. However, cancer therapies often have long-term side effects....

    Annet Nicole Linders, Itamar Braga Dias, ... Peter Van der Meer in npj Aging

    Article Open access 23 January 2024
    

18. Mesenchymal stromal cells confer breast cancer doxorubicin resistance by producing hyaluronan

    Chemotherapy resistance represents a major cause of therapeutic failure and mortality in cancer patients. Mesenchymal stromal cells (MSCs), an...

    Zhanhong Liu, Pengbo Hou, ... Yufang Shi in Oncogene

    Article 14 September 2023
    

19. Targeted CRISPR activation and knockout screenings identify novel doxorubicin transporters

    Purpose

    Tissue-specific drug uptake has not been well studied, compared to the deeper understanding of drug resistance mediated by the cellular efflux...

    Yufeng Li, Minkang Tan, ... Baoxu Pang in Cellular Oncology

    Article Open access 31 July 2023
    

20. Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells

    Drug resistance represents a major problem in cancer treatment. Doxorubicin (adriamycin) is an injectable DNA intercalating drug that halts cancer...

    Himani Shah, Timothy A. Hill, ... David P. Fairlie in Journal of Cell Communication and Signaling

    Article 22 November 2023